NCT06793982 Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain
| NCT ID | NCT06793982 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | LifeBridge Health |
| Condition | Hip Osteoarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2024-02-21 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 54 participants in total. It began in 2024-02-21 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 21-80 years * Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III Hip osteoarthritis * Indicated for a Hip injection to treat Hip OA symptoms Exclusion Criteria: * Any injections into the target Hip within three months * Current overlying skin infection * Current or previous diagnosis of "chronic pain" * Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.) * Allergy to any potential ingredients or medications utilized in any of the two groups * Treatment with another investigational drug or other intervention for pain * Diagnosis of Diabetes Mellitus * If female, pregnant or planning to be pregnant within the following 3 months or study duration * Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06793982 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 80 Years, studying Hip Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06793982 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06793982 currently recruiting?
Yes, NCT06793982 is actively recruiting participants. Contact the research team at mgesheff@lifebridgehealth.org for enrollment information.
Where is the NCT06793982 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT06793982 clinical trial?
NCT06793982 is sponsored by LifeBridge Health. The trial plans to enroll 54 participants.